Search Results 1991-2000 of 20878 for TIA

  1. ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve - Mayo Clinic

    Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study ...

  2. Vascular centers - Doctors - Mayo Clinic

    ... Transient ischemic attack, Aortic aneurysm, Thoracic aortic aneurysm, Abdominal aortic aneurysm, Peripheral artery disease, Deep vein thrombosis ...

  3. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

    ... transient ischemic attack; pulmonary embolism or other venous thromboembolism * Known active tuberculosis * Has had an allogeneic tissue/solid organ transplant

  4. Carotid endarterectomy - Doctors & Departments - Mayo Clinic

    Related. Carotid artery disease · CREST Trial · Stroke · Transient ischemic attack (TIA). Show more related content. News from Mayo Clinic. Manage your risk of ...

  5. 221AD301 Phase 3 Study Of Aducanumab (BIIB037) In Early Alzheimer's Disease - Mayo Clinic

    Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening. Brain MRI performed at Screening (per ...

  6. Cardiovascular Medicine - Clinical trials

    ... TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

  7. Neurology - Doctors - Mayo Clinic

    ous malformations, Transient ischemic attack, Amaurosis fugax, Vascular dementia, Venous thrombosis, Intracranial hematoma, Intracerebral hemorrhage ...

  8. Neurology - Doctors - Mayo Clinic

    Learn about the expertise and advanced diagnostic and treatment services for people with complex or serious conditions of the nervous system.

  9. Pulmonary Medicine - Clinical trials

    ... TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

  10. Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus - Mayo Clinic

    Stroke or transient ischemic attack. General safety: 25. Significant systemic or major illnesses other than liver disease and pulmonary disease, organ ...